Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. - Wikidata - wikimedia - TriplyDB

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.

http://www.wikidata.org/entity/Q45287769

about

Adoptive cell transfer: a clinical path to effective cancer immunotherapy The urgent need to recover MHC class I in cancers for effective immunotherapy Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Combining radiation and immunotherapy: a new systemic therapy for solid tumors?Genetic engineering with T cell receptors Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Control of the immune response by pro-angiogenic factors Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines Combining radiotherapy and cancer immunotherapy: a paradigm shift Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Engineering New Approaches to Cancer Vaccines T cell exclusion, immune privilege, and the tumor microenvironment Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.Rapid maturation of effector T cells in tumors, but not lymphoid organs, during tumor regression.Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.Induction of resident memory T cells enhances the efficacy of cancer vaccine Limited transplantation of antigen-expressing hematopoietic stem cells induces long-lasting cytotoxic T cell responses Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.Immunology of naturally transmissible tumours.Strategies to overcome obstacles to successful immunotherapy of melanoma Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells.A screening assay to identify agents that enhance T-cell recognition of human melanomas Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells.Immunotherapy for metastatic solid cancers CpG oligodeoxynucleotides enhance the efficacy of adoptive cell transfer using tumor infiltrating lymphocytes by modifying the Th1 polarization and local infiltration of Th17 cells Dendritic-cell-based therapeutic cancer vaccines Translating tumor antigens into cancer vaccines Interferon γ limits the effectiveness of melanoma peptide vaccines.PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines CD8+ T-cell memory in tumor immunology and immunotherapy.

P2860

Q24644774-D3231751-A3FE-4106-B0AA-E70C0E70DCED Q26770165-D68C0A88-4C07-4C17-82C2-7A5B6C84F72C Q26796314-FA0E8E2C-0DDB-40E7-B468-B31840BE178C Q26991721-859D42DA-47B8-4783-90D7-CF6E22FD3AE2 Q26995677-ACCE4D37-E86A-4AF8-A4F6-AE4348BAC7A7 Q27003955-FA2E6043-3451-4BB9-9650-DFDE005633B8 Q27004733-F7930150-B728-4FBD-8119-577B8D554127 Q27013679-5034A713-5013-4DF7-AC19-9ABD416A82D3 Q27021428-FA8165F8-7DEC-4E22-A4D7-8C692A541F23 Q28066199-3239959A-F499-4401-9F45-5F1DFBB89CA2 Q28085563-5A12065C-D466-4C63-A4DC-C693BC9CFB98 Q28259872-BBEAE1B2-334E-4C9D-85EA-3DB23226E60D Q28269352-DF04CCF8-6F32-48A3-8535-E2F1745F79E6 Q28749647-D2EBF34E-DD1E-4D1F-8C49-6D67513C7BB3 Q30415355-36E8185E-29B5-42A0-AF26-35FBF99AE478 Q30425111-F71D9327-A530-448F-8897-B807D1101546 Q30434822-90E4BF60-260F-44A7-B875-2D728CF6F27D Q30436792-2D0CA53D-8A36-455B-A875-3F40E694DB69 Q33261122-1C3C03B5-557E-4EC5-8855-B8B60BB1CF75 Q33296983-33816885-9E94-4A1D-AA1A-B8906392F785 Q33299427-3F67015D-08DC-4F02-8DAF-CD3CFF8038BA Q33529578-B92DF734-59DF-4D9A-B75E-2127110CE834 Q33761198-BDCA5ECF-0655-456B-94D4-0F50903A1934 Q33838390-86DE277E-005E-4B24-974F-7FA90D60DF73 Q33954123-A2167D66-2465-4C4F-AB3F-680DF0B5EBEF Q34041901-652233FE-8BBB-43E5-8501-CF14FF57679C Q34042968-D84A3D39-0813-4CA6-9A8A-4760CEBA5977 Q34067493-8D808E67-D60B-45A1-A133-1AD9DA818D8C Q34074758-5F60AEF5-ECBE-4739-94AE-FE3CFF1D522F Q34076126-6A13F692-4FE7-4605-86AF-D66F58CDCC10 Q34163771-0CE1F711-44F9-4B92-9CB0-DE8EE8537178 Q34219970-1FFF67C0-BA64-4E13-8496-074B9845B473 Q34235739-AACA52EE-C3E1-4FB8-A1BD-98B7907DABED Q34360094-AF53CDFE-F3E5-4B8E-A4CC-D31BACEF45D5 Q34484042-290025AB-EA7C-49AC-82A6-BA3ED18AC9AA Q34568835-669C4D62-C65E-42D5-9069-693D8BC103D4 Q34606735-6AC9DE1F-F0DF-4FF7-B818-0DA6101A5426 Q34612637-6715FAB3-1CEA-4957-92DD-865F7074B5FF Q34657707-3A7C5D7C-1E69-4C5C-B537-76ECC6AC5DAA Q34768139-1894C194-4212-4276-AA74-FCEFD2D906E4

P2860

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.

http://www.wikidata.org/entity/Q45287769

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Tumor progression can occur de ...... lls in patients with melanoma.

@en

Tumor progression can occur de ...... lls in patients with melanoma.

@nl

type

label

Tumor progression can occur de ...... lls in patients with melanoma.

@en

Tumor progression can occur de ...... lls in patients with melanoma.

@nl

prefLabel

Tumor progression can occur de ...... lls in patients with melanoma.

@en

Tumor progression can occur de ...... lls in patients with melanoma.

@nl

P1433

Q45287769-3539CC8F-49FD-4E75-A0D9-99849934DEF2

P1476

Q45287769-B592CCBA-6C41-4214-A5BC-A150A806CA2E

P2093

Q45287769-0B17A376-CADC-477D-B92D-5592E1E826FA

Q45287769-0D3F0AE3-C409-4B4E-998C-652CE83F0635

Q45287769-168BE277-5BBA-454C-B0CE-F9284A28DE23

Q45287769-2438C480-D3DB-4906-B6BC-31FF3DACF008

Q45287769-2B4C554B-891E-4643-BDC1-1D17D9F804BC

Q45287769-2CF769A2-6376-48E0-A673-D0749C1DE5C3

Q45287769-332CF73B-172F-404F-AE18-F4D956C8869C

Q45287769-420EF15D-8913-4F99-A3FC-E1FCE83BBCC0

Q45287769-46ED1290-9F80-41D7-896D-3B20E754E8DA

Q45287769-4F77A154-9F33-4F67-9F75-4539ED2C67C6

P304

Q45287769-162EF7EB-737A-4FE9-A5F7-48880958BA73

P31

Q45287769-E226935B-46AB-430E-84B0-1CAA15121CF4

P356

Q45287769-51BA7B3B-3570-4CC4-9A1F-D5933FA225DC

P407

Q45287769-56A0AD8E-914C-4AD2-A657-92D4D46F6B64

P433

Q45287769-4FF8A884-772E-4C28-820D-30A7DF9C422A

P478

Q45287769-ED5634AB-3D37-4098-B69D-13E2AB77631F

P577

Q45287769-41C8C30B-F0CD-4A97-B988-EFA4B2305015

P5875

Q45287769-EEE37CAA-1542-4982-8ADA-165029BE0D7E

P698

Q45287769-F3C21A58-AA72-4363-B104-DBD5F1F1C369

P921

Q45287769-FF8955D9-9CC1-4189-8FFD-885AD75F4411

P356

JIMMUNOL.175.9.6169

P1433

Journal of Immunology

P1476

Tumor progression can occur de ...... lls in patients with melanoma.

@en

P2093

David M Berman

http://www.w3.org/2001/XMLSchema#string

Donald E White

http://www.w3.org/2001/XMLSchema#string

Douglas Schwartzentruber

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

Kathleen E Morton

http://www.w3.org/2001/XMLSchema#string

Lien T Ngo

http://www.w3.org/2001/XMLSchema#string

Marybeth S Hughes

http://www.w3.org/2001/XMLSchema#string

Nicholas P Restifo

http://www.w3.org/2001/XMLSchema#string

Richard E Royal

http://www.w3.org/2001/XMLSchema#string

Richard M Sherry

http://www.w3.org/2001/XMLSchema#string

P304

6169-6176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.175.9.6169

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7529627

http://www.w3.org/2001/XMLSchema#string

P698

16237114

http://www.w3.org/2001/XMLSchema#string

P921